Riskpilot← Back to searchSign inGet full accessCarumed AB
ABActiveOrg 5569281917Nitgatan 11Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20135-9 employees
Revenue 2024
SEK 9,2M
-1% vs 2023
EBITDA margin
-3.4%
-126% vs 2023
Equity ratio
28.4%
Financial strength
Net profit 2024
SEK 62K
-91% vs 2023
| Revenue | SEK 9,2M | -1% |
| EBITDA | SEK -310K | -126% |
| Net profit | SEK 62K | -91% |
| Total assets | SEK 2,5M | -26% |
| Equity | SEK 719K | -36% |
| Employees | — | — |
Legal name
Carumed AB
Org number
5569281917
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9 april 2013
Share capital
SEK 50 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska huvudsakligen bedriva försäljning av sjukvårdsutensilier, men även andra produkter som miljövänliga bordsprodukter (även ätbara produkter: livsmedel).
Address
Nitgatan 11
Phone
+4646734100
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 131 | 7 501 | 8 600 | 9 277 | 9 222 |
| Staff expenses | — | — | −1 397 | −1 174 | −1 669 |
| EBITDA | 464 | 360 | 548 | 1 190 | −310 |
| Depreciation & amort. | −37 | −7 | −7 | −1 | −8 |
| EBIT | 427 | 353 | 541 | 1 189 | −318 |
| Net financials | −33 | −7 | −26 | −6 | −8 |
| Profit before tax | 293 | 258 | 386 | 874 | 96 |
| Tax | −64 | −54 | −81 | −191 | −34 |
| Net profit | 229 | 204 | 305 | 684 | 62 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 439 | 2 162 | 2 409 | 3 445 | 2 532 |
| Equity | 1 078 | 893 | 877 | 1 122 | 719 |
| Long-term debt | 0 | 150 | 72 | 0 | 100 |
| Short-term debt | 1 156 | 826 | 1 038 | 1 592 | 1 405 |
| Total debt | 1 156 | 976 | 1 110 | 1 592 | 1 505 |
EBITDA margin
-3.4%
This company
15.8%
Market median
-122% vs market
20202024
Equity ratio
28.4%
This company
38.2%
Market median
-26% vs market
20202024
Return on equity
8.7%
This company
18.4%
Market median
-53% vs market
20202024
Net profit margin
0.7%
This company
8.1%
Market median
-91% vs market
20202024
Asset turnover
3.64×
This company
1.12×
Market median
+225% vs market
20202024
Debt / equity
2.52×
This company
0.62×
Market median
-306% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UG Chief Auditor | Chief Auditor | 2026 |
| Former (1) | ||
LV | Audit | 2021 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2026 | |
| Chairman | 2026 | |
| Board of Directors | 2026 | |
| Former (2) | ||
| Board of Directors | 2021 – 2026 | |
| Board of Directors | 2021 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Carumed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Linda Viktoria Sjöberg | Audit | 0 companies |
| Ulf Greger Johansson Längvik | Chief Auditor | 0 companies |
| Edoard Eddie Dieck | Board of Directors | 0 companies |
| Stefan Roland Johannes Wilhelmsson | Chairman | 0 companies |
| Björn Wincent Moffat Hartzén | Board of Directors | 0 companies |
| Carlos Vilhelm Wilhelmsson | Board of Directors | 0 companies |
| Amie Ann-Marie Elisabet Hartzén | Board of Directors | 0 companies |